Formulation & Evaluation Of Mucoadhesive Tablet Of Ranolazine

Ranolazine is an anti-anginal drug with extensive and highly variable hepatic first pass metabolism following oral administration, with systemic bio-availability of 76% and ranolazine also has a relatively short plasma half-life of 2.5+0.5 hours. Ranolazine, a promising therapeutic agent for the management of chronic angina, poses challenges in its conventional tablet formulation due to its low bioavailability and short half-life. To address these limitations, novel drug delivery systems (NDDS) offer innovative approaches to enhance drug efficacy and patient compliance. This research paper explores the development of ranolazine tablets utilizing both NDDS and mucoadhesive drug delivery systems (MDDS). The study investigates various formulation strategies, including nanoparticle encapsulation, liposomal delivery, and mucoadhesive polymer incorporation, aimed at improving drug solubility, stability, and targeted delivery to the site of action. Evaluation of the developed formulations includes in vitro characterization studies such as drug release kinetics, mucoadhesive properties, and pharmacokinetic profiling. The findings demonstrate the potential of NDDS and MDDS in optimizing the delivery of ranolazine, thereby offering promising avenues for enhanced therapeutic outcomes in the management of chronic angina.